Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 11/20 | 0.47 |
| ▸ | TMPRSS15 | P98073 | 11/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008631 | 0.82 | KMT2A (0.49) | PRSS1TMPRSS15TDP1ATML3MBTL1 | |
| SCHEMBL4335496 | 0.82 | NR1H4 (0.50) | TDP1ATML3MBTL1MAPTPARP10 | |
| SCHEMBL7324570 | 0.81 | MAPT (0.61) | PRSS1TDP1L3MBTL1MAPTKMT2A | |
| SCHEMBL20008702 | 0.81 | PRSS1 (0.47) | PRSS1TMPRSS15TDP1L3MBTL1KMT2A | |
| SCHEMBL20008625 | 0.80 | PLG (0.43) | PRSS1TMPRSS15TDP1L3MBTL1MAPT | |
| SCHEMBL20012325 | 0.80 | NR1H4 (0.43) | TDP1ATML3MBTL1MAPTKMT2A | |
| SCHEMBL6674203 | 0.80 | ESR1 (0.57) | TDP1ATML3MBTL1MAPTKMT2A | |
| SCHEMBL8844966 | 0.80 | TDP1 (0.60) | TDP1ATML3MBTL1MAPTTNF | |
| SCHEMBL11392449 | 0.80 | MAPT (0.49) | TDP1ATML3MBTL1MAPTKMT2A | |
| Benzamide SCHEMBL21771957 | 0.80 | TDP1 (0.54) | PRSS1TDP1ATML3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885TDP1 1454/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885TDP1 1454/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885TDP1 1454/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885TDP1 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.